QQ客服 官方微博 反馈留言

	Pharmacologic characterization of fluzoparib, a novel poly polymerase inhibitor undergoing clinical trials
	Lei Wang; Changyong Yang; Chengying Xie; Jiahua Jiang; Mingzhao Gao; Li Fu; Yun Li; Xubin Bao; Haoyu Fu; Liguang Lou
刊名	Cancer Science
	2019
卷号	Vol.110 No.3页码:1064-1075
关键词	antitumor activity fluzoparib pharmacokinetics poly(ADP‐ribose) polymerase toxicity
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4611399
专题	湖南大学
作者单位	1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China 2.Jiangsu Hengrui Medicine Co Ltd, Lianyungang, China 3.Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China 4.Jiangsu Province Hi‐Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing, China 5.Liguang Lou, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
推荐引用方式 GB/T 7714	Lei Wang,Changyong Yang,Chengying Xie,et al. Pharmacologic characterization of fluzoparib, a novel poly polymerase inhibitor undergoing clinical trials[J]. Cancer Science,2019,Vol.110 No.3:1064-1075.
APA	Lei Wang.,Changyong Yang.,Chengying Xie.,Jiahua Jiang.,Mingzhao Gao.,...&Liguang Lou.(2019).Pharmacologic characterization of fluzoparib, a novel poly polymerase inhibitor undergoing clinical trials.Cancer Science,Vol.110 No.3,1064-1075.
MLA	Lei Wang,et al."Pharmacologic characterization of fluzoparib, a novel poly polymerase inhibitor undergoing clinical trials".Cancer Science Vol.110 No.3(2019):1064-1075.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。